• Overview
  • News
  • Analysis
  • Recos
  • Financials
  • Technicals
  • Peers
  • Shareholdings
  • MF
  • Corp Actions
  • About

Insights

View All

  • Company has spent 1.97% of its operating revenues towards interest expenses and 10.19% towards employee cost in the year ending Mar 31, 2020. (Source: Consolidated Financials)

  • Stock gave a 3 year return of 62.4% as compared to Nifty Smallcap 100 which gave a return of 32.92%. (as of last trading session)

  • Stock generated 62.4% return as compared to Nifty Pharma which gave investors 36.87% return over 3 year time period. (as of last trading session)

InsightsSMS Lifesciences India Ltd.

  • Employee & Interest Expense

    Company has spent 1.97% of its operating revenues towards interest expenses and 10.19% towards employee cost in the year ending Mar 31, 2020. (Source: Consolidated Financials)

  • Stock Returns vs Nifty Smallcap 100

    Stock gave a 3 year return of 62.4% as compared to Nifty Smallcap 100 which gave a return of 32.92%. (as of last trading session)

  • Stock Returns vs Nifty Pharma

    Stock generated 62.4% return as compared to Nifty Pharma which gave investors 36.87% return over 3 year time period. (as of last trading session)

Do you find these insights useful?

  • hate it

  • meh

  • love it

Key Metrics

  • 14.96
  • 48.60
  • 219.81
  • 73
  • 1.91
  • 0.21
  • 10.00
  • 1.45
  • 723.72

Returns

  • 1 Day-0.32%
  • 1 Week-0.87%
  • 1 Month2.97%
  • 3 Months21.32%
  • 1 Year59.63%
  • 3 Years61.87%
  • 5 YearsN.A.

SMS Lifesciences Ind Stock Analysis

EARNINGS
FUNDAMENTAL
RELATIVE VALUATION
RISK
PRICE MOMENTUM

NO RATING (NR)

NEGATIVE (1-3)

NEUTRAL (4-7)

POSITIVE (8-10)

In-depth Reports on 4000+ Indian Stocks worth ₹1,499 with ET Prime membership

START FREE TRIAL

Recommendations

Financials

  • Income (P&L)

  • Balance Sheet

  • Cash Flow

  • Ratios

  • Insights

    • Employee & Interest Expense

      Company has spent 1.97% of its operating revenues towards interest expenses and 10.19% towards employee cost in the year ending Mar 31, 2020. (Source: Consolidated Financials)
    Quarterly | AnnualJun 2021Mar 2021Dec 2020Sep 2020Jun 2020
    Total Income76.3483.7967.1862.0455.05
    Total Income Growth (%)-8.8924.728.2912.6917.50
    Total Expenses70.1976.0661.8555.7650.30
    Total Expenses Growth (%)-7.7222.9810.9310.8513.21
    EBIT6.157.735.336.284.75
    EBIT Growth (%)-20.4644.93-15.1132.2596.14
    Profit after Tax (PAT)3.635.052.703.312.48
    PAT Growth (%)-28.2287.48-18.6933.5357.89
    EBIT Margin (%)8.059.237.9410.138.63
    Net Profit Margin (%)4.756.034.015.344.51
    Basic EPS (₹)12.0016.728.9210.968.21
    Quarterly | AnnualJun 2021Mar 2021Dec 2020Sep 2020Jun 2020
    Total Income73.2780.6966.0160.7354.86
    Total Income Growth (%)-9.2022.258.6910.7017.32
    Total Expenses68.0973.7959.8054.7450.09
    Total Expenses Growth (%)-7.7323.399.259.2912.70
    EBIT5.186.906.205.994.77
    EBIT Growth (%)-24.9511.213.6425.52106.09
    Profit after Tax (PAT)2.903.953.573.132.51
    PAT Growth (%)-26.7010.7614.0124.5370.91
    EBIT Margin (%)7.078.559.409.868.69
    Net Profit Margin (%)3.964.905.415.164.58
    Basic EPS (₹)9.5913.0811.8110.368.32
    Quarterly | Annual FY 2020
    Total Revenue263.06
    Total Revenue Growth (%)-30.84
    Total Expenses248.39
    Total Expenses Growth (%)-30.03
    Profit after Tax (PAT)10.18
    PAT Growth (%)-42.94
    Operating Profit Margin (%)7.59
    Net Profit Margin (%)3.90
    Basic EPS (₹)33.68
    Quarterly | Annual FY 2020 FY 2019 FY 2018 FY 2017
    Total Revenue258.81346.68216.07217.62
    Total Revenue Growth (%)-25.3560.45-0.71-
    Total Expenses245.47322.92209.67199.16
    Total Expenses Growth (%)-23.9854.025.281.08
    Profit after Tax (PAT)9.1516.636.5012.94
    PAT Growth (%)-45.01155.85-49.77-
    Operating Profit Margin (%)7.178.494.9611.40
    Net Profit Margin (%)3.564.833.055.99
    Basic EPS (₹)30.2655.0221.5042.81

    All figures in Rs Cr, unless mentioned otherwise

  • Annual FY 2020
    Total Assets252.83
    Total Assets Growth (%)-6.29
    Total Liabilities137.10
    Total Liabilities Growth (%)-16.13
    Total Equity115.73
    Total Equity Growth (%)8.84
    Current Ratio (x)1.23
    Total Debt to Equity (x)0.50
    Contingent Liabilities71.12
    Annual FY 2020 FY 2019 FY 2018 FY 2017
    Total Assets228.95250.70176.65175.24
    Total Assets Growth (%)-8.6841.920.80-
    Total Liabilities115.69145.7288.2593.40
    Total Liabilities Growth (%)-20.6165.12-5.510.09
    Total Equity113.26104.9888.4181.84
    Total Equity Growth (%)7.8918.748.03-
    Current Ratio (x)1.271.201.391.38
    Total Debt to Equity (x)0.390.380.240.24
    Contingent Liabilities83.1654.1741.0165.42

    All figures in Rs Cr, unless mentioned otherwise

  • Insights

    • Decrease in Cash from Investing

      Company has used Rs 13.28 cr for investing activities which is an YoY decrease of 69.32%. (Source: Standalone Financials)
    Annual FY 2020
    Net Cash flow from Operating Activities14.55
    Net Cash used in Investing Activities-27.02
    Net Cash flow from Financing Activities12.45
    Net Cash Flow-0.03
    Closing Cash & Cash Equivalent2.15
    Closing Cash & Cash Equivalent Growth (%)-1.24
    Total Debt/ CFO (x)3.96
    Annual FY 2020 FY 2019 FY 2018 FY 2017
    Net Cash flow from Operating Activities13.9527.268.0019.66
    Net Cash used in Investing Activities-13.28-43.27-6.84-7.53
    Net Cash flow from Financing Activities-2.0517.60-0.81-12.34
    Net Cash Flow-1.381.590.36-0.21
    Closing Cash & Cash Equivalent0.652.030.440.08
    Closing Cash & Cash Equivalent Growth (%)-67.77365.97463.78-
    Total Debt/ CFO (x)3.201.472.651.02

    All figures in Rs Cr, unless mentioned otherwise

  • Annual FY 2020
    Return on Equity (%)8.79
    Return on Capital Employed (%)11.94
    Return on Assets (%)4.02
    Interest Coverage Ratio (x)3.86
    Asset Turnover Ratio (x)103.14
    Price to Earnings (x)5.20
    Price to Book (x)0.46
    EV/EBITDA (x)3.72
    EBITDA Margin (%)10.60
    Annual FY 2020 FY 2019 FY 2018 FY 2017
    Return on Equity (%)8.0715.847.3515.81
    Return on Capital Employed (%)12.3520.529.3722.96
    Return on Assets (%)3.996.633.687.38
    Interest Coverage Ratio (x)3.625.352.533.99
    Asset Turnover Ratio (x)112.22137.27120.56123.19
    Price to Earnings (x)5.7910.0417.57-
    Price to Book (x)0.471.591.29-
    EV/EBITDA (x)3.715.848.27-
    EBITDA Margin (%)9.9910.167.6413.97

Financial InsightsSMS Lifesciences India Ltd.

  • Income (P&L)
  • Cash Flow
    • Employee & Interest Expense

      Company has spent 1.97% of its operating revenues towards interest expenses and 10.19% towards employee cost in the year ending Mar 31, 2020. (Source: Consolidated Financials)

    • Decrease in Cash from Investing

      Company has used Rs 13.28 cr for investing activities which is an YoY decrease of 69.32%. (Source: Standalone Financials)

Do you find these insights useful?

  • hate it

  • meh

  • love it

Technicals

  • Buy / Sell Signals

  • Price Analysis

  • Pivot Levels & ATR

  • Chart

  • Stock doesnt have any Buy/Sell Signals.

  • Price Analysis Data details are not available.

  • Pivot Levels

    R1R2R3PIVOTS1S2S3
    Classic-------

    Average True Range

    5 DAYS14 DAYS28 DAYS
    ATR---

Peer Comparison

  • Stock Performance

  • Ratio Performance

    • CHART
    • TABLE

    Insights

    • Stock Returns vs Nifty Smallcap 100

      Stock gave a 3 year return of 62.4% as compared to Nifty Smallcap 100 which gave a return of 32.92%. (as of last trading session)
    • Stock Returns vs Nifty Pharma

      Stock generated 62.4% return as compared to Nifty Pharma which gave investors 36.87% return over 3 year time period. (as of last trading session)
    • 1D
    • 1W
    • 1M
    • 3M
    • 6M
    • 1Y
    • 5Y
  • Insights

    • Stock Returns vs Nifty Smallcap 100

      Stock gave a 3 year return of 62.4% as compared to Nifty Smallcap 100 which gave a return of 32.92%. (as of last trading session)
    • Stock Returns vs Nifty Pharma

      Stock generated 62.4% return as compared to Nifty Pharma which gave investors 36.87% return over 3 year time period. (as of last trading session)

    Ratio Performance

    NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
    SMS Lifesciences Ind14.961.908.7911.944.026.467.593.9033.681.230.503.96
    Albert David9.691.339.0610.776.48-3.6711.358.9438.802.770.000.02
    Bafna Pharma50.245.4010.2610.566.73-2.839.228.182.462.040.04-0.18
    Brooks Labs-17.033.05-24.76-9.06-15.446.66-14.58-34.97-13.840.830.24-2.56
    Kilitch Drug43.412.230.711.920.5824.204.351.570.552.540.113.37
    Add More

    Annual Ratios (%)

    Choose from Peers

    • Wanbury Ltd
    • Mangalam Drugs
    • Lyka Labs
    • Vivimed Labs
    • Bal Pharma

    See All Parameters

Peers InsightsSMS Lifesciences India Ltd.

  • Stock Returns vs Nifty Smallcap 100

    Stock gave a 3 year return of 62.4% as compared to Nifty Smallcap 100 which gave a return of 32.92%. (as of last trading session)

  • Stock Returns vs Nifty Pharma

    Stock generated 62.4% return as compared to Nifty Pharma which gave investors 36.87% return over 3 year time period. (as of last trading session)

Do you find these insights useful?

  • hate it

  • meh

  • love it

Shareholding Pattern

  • QOQ Change

  • Total Shareholdings

  • Showing Shareholding as on 30 Jun 2021

    Category30 Jun 202131 Mar 202131 Dec 202030 Sep 2020
    Promoters67.7468.2668.2668.24
    Pledge3.543.513.518.71
    FII0.000.000.000.00
    DII0.000.000.000.00
    Mutual Funds0.000.000.000.00
    Others32.2631.7431.7431.76
  • Showing Shareholding as on 30 Jun 2021

    CategoryNo. of SharesPercentage% Change QoQ
    Promoters20,48,11767.74 %-0.52
    Pledge72,5203.54 %0.03
    DII5,1570.17 %0.00
    Others9,70,01332.26 %0.52

MF Ownership

MF Ownership details are not available.

Top Searches:

Corporate Actions

  • Board Meeting/AGM

  • Dividends

  • Others
  • Meeting DateAnnounced onPurposeDetails
    Aug 13, 2021Aug 09, 2021Board MeetingQuarterly Results
    Jun 18, 2021Jun 07, 2021Board MeetingAudited Results & Dividend
    Jun 07, 2021Jun 07, 2021Board MeetingAudited Results & Dividend
    Feb 12, 2021Feb 08, 2021Board MeetingQuarterly Results
    Nov 13, 2020Nov 09, 2020Board MeetingQuarterly Results
  • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
    Final15%1.5Sep 19, 2019May 30, 2019
    Final15%1.5-Jun 18, 2021
  • No other corporate actions details are available.

About SMS Lifesciences Ind

SMS Lifesciences India Ltd., incorporated in the year 2006, is a Small Cap company (having a market cap of Rs 219.81 Crore) operating in Pharmaceuticals sector. SMS Lifesciences India Ltd. key Products/Revenue Segments include Pharmaceuticals and Export Incentives for the year ending 31-Mar-2020. Show More

  • Executives

  • Auditors

  • TM

    TVVSN Murthy

    Managing Director

    RB

    Ramesh Babu Potluri

    Non Executive Director

    PS

    P S Rao

    Independent Director

    PS

    P Sarath Kumar

    Independent Director

    Show More

Address

Plot No.19-III,Road No.71, Jubilee Hills,Opp. Bharatiya Vidya Bhavan Public School,Hyderabad, Telangana - 500096

More Details

SMS Lifesciences Ind Share Price Update

SMS Lifesciences India Ltd. share price moved down by -0.32% from its previous close of Rs 729.40. SMS Lifesciences India Ltd. stock last traded price is 727.05

Share PriceValue
Today/Current/Last727.05
Previous Day729.40

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.

Tell us about you

Find us at the office

Eastmond- Sukel street no. 62, 79540 Hanga Roa, Easter Island

Give us a ring

Jaquelinee Wrate
+74 201 709 645
Mon - Fri, 9:00-15:00

Reach out